Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study
Andrea Chiricozzi(Università Cattolica del Sacro Cuore), Ketty Peris(Agostino Gemelli University Polyclinic), Simone Ribero, Giampiero Girolomoni(University of Verona), Niccolò Gori(Università Cattolica del Sacro Cuore), Lucia Di Nardo(Università Cattolica del Sacro Cuore), Curdin Conrad(University of Lausanne), Marco Galluzzo(University of Rome Tor Vergata), Anna Balato(University of Campania "Luigi Vanvitelli"), Michela Ortoncelli, Tina Seremet(University of Lausanne), Giuseppe Argenziano(Regione Campania), Giacomo Caldarola(Università Cattolica del Sacro Cuore), Tiago Torres(Universidade do Porto), Clara De Simone(IRCCS San Camillo Hospital), Silvia Mariel Ferrucci(University of Milan), Spyridon Gkalpakiotis(Charles University), Minia Campos‐Domínguez(Universitat Autònoma de Barcelona), AV Marzano(University of Milan), JM Carrascosa(Universitat Autònoma de Barcelona), Martina Maurelli(University of Verona), Elena Ippoliti(Università Cattolica del Sacro Cuore), Luca Bianchi(University of Rome Tor Vergata)
Cited by 0
Related Papers
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
|Clinical Reviews in Allergy & Immunology|2018|738
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
|European Journal of Cancer|2016|579
Regulatory Activity of Autocrine IL-10 on Dendritic Cell Functions
|The Journal of Immunology|2001|553
Scanning the Immunopathogenesis of Psoriasis
|International Journal of Molecular Sciences|2018|317